| abstract |
In the invention, a pharmaceutical composition is provided, comprising a first and a second peptide. The first peptide is a peptide of the bacteriocin PLNC8 αβ, wherein the peptide of the bacteriocin PLNC8 αβ is a peptide A having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (%SI) with SEQ ID NO 1, or a peptide B having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (%SI) with SEQ ID NO 2. When the first peptide is peptide A, the second peptide B' having 14 to 34 amino acids and comprising a peptide having at least 90%>, 95%>, 96%>, 97%>, 98%> or 99% sequence identity (%SI) with SEQ ID NO 3. When the first peptide is peptide B, the second peptide A' having 15 to 29 amino acids and comprising a peptide having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (%SI) with SEQ ID NO 4. The pharmaceutical composition further comprises at least one antibiotic. The pharmaceutical composition may be used in the treatment or prophylaxis of a bacterial infection. |